Joint hypermobility linked to longer COVID-19 recovery time

FHS
March 20, 2024
11:16 pm

Study shows that individuals with generalized joint hypermobility have a 30% higher risk of not recovering from acute COVID-19, highlighting the need for tailored treatment and care.

Will slow uptake of Leqembi pose a risk to Biogen’s recovery?

If Biogen’s dismal stock performance on Tuesday is any indication, Leqembi could be the single biggest factor in the company’s ability to right the ship.

February 15, 2024

Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

November 15, 2024

Children with mitochondrial disorders have weaker antibody response to viral infections, study finds

In a new study, National Institutes of Health (NIH) researchers found that altered B cell function in children with mitochondrial disorders led to a weaker

July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.